Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across cancer, cardiovascular disease and inflammation

          Learn more

        • Cancer
        • Inflammation
        • Cardiovascular
        • Programs
        • Laboratories
        • Diseases
        • Expertises
        • Services and instrumentation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your Will
        • Donate in Memory
  • Impact
        • Impact

          Our research develops new diagnostics, treatments and cures for some of the most deadly and debilitating diseases affecting society today

          Learn more

        • Breakthroughs
        • Community and research
        • Real stories
  • Health hub
        • Health hub

          A range of practical information to assist in the possible preventions to disease through evidence-based research on how the body works.

          Learn more

        • Inflammation
        • The Good Gut Anti-Inflammatory Diet
        • Ageing
        • Exercise Snack Program
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
        • Careers and studies
        • Contact
  • Donate
    Centenary Institute > News > New treatment hope for asthma and COPD

New treatment hope for asthma and COPD

Date time 20 August, 2020
News Type News type Research News
An international study led by the University of Glasgow, including collaborators from the Centenary Institute, has identified a new class of drugs that could pave the way to a new treatment for asthma and chronic obstructive pulmonary disease (COPD).

An international study led by the University of Glasgow, including collaborators from the Centenary Institute, has identified a new class of drugs that could pave the way to a new treatment for asthma and chronic obstructive pulmonary disease (COPD).

The breakthrough findings, published in the journal ‘Science Translational Medicine’, found that the drugs were able to reverse the symptoms of asthma in animal models.

Researchers also found that the same drugs, when applied to lung samples obtained from human donors, showed effects similar to those seen in the animal models.

Scientists believe that these combined findings offer new hope that these drugs could provide new medicines for human inflammatory lung disease.

The new approach is centred on the activation of a protein that, up until now has been known to respond to good fats contained in our diet. The protein, called free fatty acid receptor 4 (FFA4), is found in the gut and pancreas where it is activated by good dietary fats including the fish oil omega 3. Once activated FFA4 is known to help control levels of glucose in the blood.

Surprisingly the research team found FFA4 to be present in the human lung.

By designing a new class of drugs that activate FFA4 in the lung, the researchers found that the muscle that surrounds the airways relaxes allowing more air to enter the lung. They also found that activators of FFA4 reduced inflammation caused by exposure of mice to pollution, cigarette smoke and allergens like house dust mite that cause asthma.

In this way the researchers have established that activating FFA4 can reverse the key hallmarks of inflammatory lung disease heralding the prospect of new drugs for the treatment of lung disease.

“The study was a truly collaborative effort with some of the experimental work done here in Australia, utilising our world-class facilities, said Professor Phil Hansbro, co-author on the published study and Director of the Centenary UTS Centre for Inflammation.

“I’m optimistic that this breakthrough could lead to life-changing treatments for sufferers of asthma and COPD, both of which can be devastating and deadly diseases,” he said.

Photo (L to R): Publication co-authors from the Centenary Institute, Dr Richard Kim, Professor Phil Hansbro, Dr Chantal Donovan.

The full media release can be found here.

The research publication can be found here.

Themes

  • Inflammation

    Inflammation

Media enquires

For all media and interview enquiries, please contact Tony Crawshaw, Media and Communications Manager

Phone number Phone Number 0402 770 403

Email Email t.crawshaw@centenary.org.au

Recent Stories

  • Research to unlock the secrets of muscle loss in ageing

    The Centenary Institute and the University of Technology Sydney will lead pioneering research into age-related muscle loss, called sarcopenia, with a Dynamic Resilience Program contract from Wellcome Leap.
    News Type: Media release
    Date 28 Sep 2023
  • New treatment offers hope for advanced liver cancer

    Researchers have discovered a new way to treat hepatocellular carcinoma (HCC), the most common type of liver cancer and the third leading cause of cancer death worldwide.
    News Type: Media release
    Date 26 Sep 2023
  • Meet Dr Bobby Boumelhem

    Dr Bobby Boumelhem, a dedicated researcher at the Centenary Institute, is on a mission to enhance the quality of life for individuals grappling with liver disease. Diseases such as hepatitis, liver cancer, non-alcoholic fatty liver disease and cirrhosis pose significant health challenges.
    News Type: Profiles
    Date 22 Sep 2023
  • Cancer drug for COVID-19

    Researchers, including Dr Matt Johansen from the Centenary UTS Centre for Inflammation and Professor Phil Hansbro, Director of the Centenary UTS Centre for Inflammation, have discovered that a cancer drug could play an important role in limiting the damaging effects of lung disease in COVID-19 patients.
    News Type: Research News
    Date 19 Sep 2023

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Programs
  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Contact Privacy

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram